@article {van Helvoorte002025, author = {Eefje Martine van Helvoort and Paco M J Welsing and Myl{\`e}ne P Jansen and Willem Paul Gielis and Marieke Loef and Margreet Kloppenburg and Francisco Blanco and Ida K Haugen and Francis Berenbaum and Anne-C Bay-Jensen and Christoph Ladel and Agnes Lalande and Jonathan Larkin and John Loughlin and Ali Mobasheri and Harrie Weinans and Floris Lafeber and Niels Eijkelkamp and Simon Mastbergen}, title = {Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping}, volume = {7}, number = {3}, elocation-id = {e002025}, year = {2021}, doi = {10.1136/rmdopen-2021-002025}, publisher = {BMJ Specialist Journals}, abstract = {Objectives Osteoarthritis (OA) patients with a neuropathic pain (NP) component may represent a specific phenotype. This study compares joint damage, pain and functional disability between knee OA patients with a likely NP component, and those without a likely NP component.Methods Baseline data from the Innovative Medicines Initiative Applied Public-Private Research enabling OsteoArthritis Clinical Headway knee OA cohort study were used. Patients with a painDETECT score >=19 (with likely NP component, n=24) were matched on a 1:2 ratio to patients with a painDETECT score <=12 (without likely NP component), and similar knee and general pain (Knee Injury and Osteoarthritis Outcome Score pain and Short Form 36 pain). Pain, physical function and radiographic joint damage of multiple joints were determined and compared between OA patients with and without a likely NP component.Results OA patients with painDETECT scores >=19 had statistically significant less radiographic joint damage (p<=0.04 for Knee Images Digital Analysis parameters and Kellgren and Lawrence grade), but an impaired physical function (p\<0.003 for all tests) compared with patients with a painDETECT score <=12. In addition, more severe pain was found in joints other than the index knee (p<=0.001 for hips and hands), while joint damage throughout the body was not different.Conclusions OA patients with a likely NP component, as determined with the painDETECT questionnaire, may represent a specific OA phenotype, where local and overall joint damage is not the main cause of pain and disability. Patients with this NP component will likely not benefit from general pain medication and/or disease-modifying OA drug (DMOAD) therapy. Reserved inclusion of these patients in DMOAD trials is advised in the quest for successful OA treatments.Trial registration numberThe study is registered under clinicaltrials.gov nr: NCT03883568.Data are available on reasonable request. In order to gain and govern access to the central IMI-APPROACH databases, tranSMART and XNAT, access has to be approved by the IMI-APPROACH Steering Committee.}, URL = {https://rmdopen.bmj.com/content/7/3/e002025}, eprint = {https://rmdopen.bmj.com/content/7/3/e002025.full.pdf}, journal = {RMD Open} }